{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:45:05Z","timestamp":1790729105426,"version":"4.1.0"},"publisher-location":"Cham","reference-count":168,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319208244","type":"print"},{"value":"9783319208251","type":"electronic"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-20825-1_9","type":"book-chapter","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T14:48:01Z","timestamp":1443192481000},"page":"261-283","source":"Crossref","is-referenced-by-count":57,"title":["Endocannabinoids and Mental Disorders"],"prefix":"10.1007","author":[{"given":"TIziana","family":"Rubino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Zamberletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Parolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"9_CR1","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/archgenpsychiatry.2011.2273","volume":"69","author":"A Agrawal","year":"2012","unstructured":"Agrawal A, Nelson EC, Littlefield AK et al (2012) Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression. Arch Gen Psychiatry 69:732\u2013740","journal-title":"Arch Gen Psychiatry"},{"key":"9_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00213-009-1532-5","volume":"205","author":"DC Aguiar","year":"2009","unstructured":"Aguiar DC, Terzian AL, Guimar\u00e3es FS et al (2009) Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl) 205:217\u2013225","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR3","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1023\/A:1020968922151","volume":"24","author":"BE Akinshola","year":"1999","unstructured":"Akinshola BE, Chakrabarti A, Onaivi ES (1999) In-vitro and in-vivo action of cannabinoids. Neurochem Res 24:1233\u20131240","journal-title":"Neurochem Res"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/FBP.0b013e3283564dfa","volume":"23","author":"M Aliczki","year":"2012","unstructured":"Aliczki M, Balogh Z, Tulogdi A et al (2012) The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature. Behav Pharmacol 23:348\u2013357","journal-title":"Behav Pharmacol"},{"key":"9_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.schres.2014.01.039","volume":"153","author":"V Almeida","year":"2014","unstructured":"Almeida V, Peres FF, Levin R et al (2014) Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain. Schizophr Res 153:150\u2013159","journal-title":"Schizophr Res"},{"key":"9_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbr.2013.05.027","volume":"252","author":"AF Almeida-Santos","year":"2013","unstructured":"Almeida-Santos AF, Gobira PH, Rosa LC et al (2013) Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray. Behav Brain Res 252:10\u201317","journal-title":"Behav Brain Res"},{"key":"9_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0091-3057(01)00578-0","volume":"70","author":"C Arevalo","year":"2001","unstructured":"Arevalo C, De Miguel R, Hernandez-Tristan R (2001) Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70:123\u2013131","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1471-4159.2007.05149.x","volume":"105","author":"E Aso","year":"2008","unstructured":"Aso E, Ozaita A, Valdiz\u00e1n EM et al (2008) BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105:565\u2013572","journal-title":"J Neurochem"},{"key":"9_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1101\/lm.53303","volume":"10","author":"SC Azad","year":"2003","unstructured":"Azad SC, Eder M, Marsicano G et al (2003) Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10:116\u2013128","journal-title":"Learn Mem"},{"key":"9_CR10","first-page":"213","volume":"14","author":"G Bagdy","year":"2012","unstructured":"Bagdy G, Juhasz G, Gonda X (2012) A new clinical evidence-based gene-environment interaction model of depression. Neuropsychopharmacol Hung 14:213\u2013220","journal-title":"Neuropsychopharmacol Hung"},{"key":"9_CR11","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1523\/JNEUROSCI.20-09-03401.2000","volume":"20","author":"M Beltramo","year":"2000","unstructured":"Beltramo M, de Fonseca FR, Navarro M et al (2000) Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 20:3401\u20133407","journal-title":"J Neurosci"},{"key":"9_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.nbd.2010.03.020","volume":"39","author":"CE Beyer","year":"2010","unstructured":"Beyer CE, Dwyer JM, Piesla MJ et al (2010) Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 39:148\u2013155","journal-title":"Neurobiol Dis"},{"key":"9_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764\u2013774","journal-title":"Neuropsychopharmacology"},{"key":"9_CR14","doi-asserted-by":"publisher","first-page":"15670","DOI":"10.1073\/pnas.0504640102","volume":"102","author":"A Bilkei-Gorzo","year":"2005","unstructured":"Bilkei-Gorzo A, Racz I, Valverde O et al (2005) Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc Natl Acad Sci USA 102:15670\u201315675","journal-title":"Proc Natl Acad Sci USA"},{"key":"9_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00213-010-2124-0","volume":"215","author":"MD Black","year":"2011","unstructured":"Black MD, Stevens RJ, Rogacki N et al (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) 215:149\u2013163","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.53","volume":"4","author":"RJ Bluett","year":"2014","unstructured":"Bluett RJ, Gamble-George JC, Hermanson DJ et al (2014) Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry 4, e408","journal-title":"Transl Psychiatry"},{"key":"9_CR17","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1038\/sj.npp.1301061","volume":"31","author":"M Bortolato","year":"2006","unstructured":"Bortolato M, Campolongo P, Mangieri RA et al (2006) Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31:2652\u20132659","journal-title":"Neuropsychopharmacology"},{"key":"9_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.biopsych.2006.12.001","volume":"62","author":"M Bortolato","year":"2007","unstructured":"Bortolato M, Mangieri RA, Fu J et al (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103\u20131110","journal-title":"Biol Psychiatry"},{"key":"9_CR19","first-page":"55","volume":"17","author":"DC Bosi","year":"2003","unstructured":"Bosi DC, Hallak JE, Dursun SM et al (2003) Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. J Psychopharmacology 17:55","journal-title":"J Psychopharmacology"},{"key":"9_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejphar.2006.10.038","volume":"555","author":"D Braida","year":"2007","unstructured":"Braida D, Limonta V, Malabarba L et al (2007) 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague\u2013Dawley rats. Eur J Pharmacol 555:156\u2013163","journal-title":"Eur J Pharmacol"},{"key":"9_CR21","doi-asserted-by":"publisher","first-page":"9800","DOI":"10.1073\/pnas.0703472104","volume":"104","author":"HD Burns","year":"2007","unstructured":"Burns HD, Van Laere K, Sanabria-Boh\u00f3rquez S et al (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 104:9800\u20139805","journal-title":"Proc Natl Acad Sci USA"},{"key":"9_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.biopsych.2011.04.022","volume":"70","author":"A Busquets-Garcia","year":"2011","unstructured":"Busquets-Garcia A, Puighermanal E, Pastor A et al (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479\u2013486","journal-title":"Biol Psychiatry"},{"key":"9_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/JCP.0000000000000180","volume":"34","author":"C Cameron","year":"2014","unstructured":"Cameron C, Watson D, Robinson J (2014) Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol 34:559\u2013564","journal-title":"J Clin Psychopharmacol"},{"key":"9_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neuroscience.2010.01.062","volume":"167","author":"AC Campos","year":"2010","unstructured":"Campos AC, Ferreira FR, Guimar\u00e3es FS et al (2010) Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety-like behaviors depending on previous stress experience. Neuroscience 167:238\u2013246","journal-title":"Neuroscience"},{"key":"9_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","volume":"79","author":"J Ceccarini","year":"2013","unstructured":"Ceccarini J, De Hert M, Van Winkel R et al (2013) Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 79:304\u2013312","journal-title":"Neuroimage"},{"key":"9_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/ajmg.b.30592","volume":"147","author":"I Chavarr\u00eda-Siles","year":"2008","unstructured":"Chavarr\u00eda-Siles I, Contreras-Rojas J, Hare E et al (2008) Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147:279\u2013284","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"9_CR27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jpsychires.2012.03.021","volume":"46","author":"K Choi","year":"2012","unstructured":"Choi K, Le T, McGuire J et al (2012) Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res 46:882\u2013889","journal-title":"J Psychiatr Res"},{"key":"9_CR28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706\u20131713","journal-title":"Lancet"},{"key":"9_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.addbeh.2009.09.007","volume":"35","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR, Kirisci L, Reynolds M et al (2010) PTSD contributes to teen and young adult cannabis use disorders. Addict Behav 35:91\u201394","journal-title":"Addict Behav"},{"key":"9_CR30","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/npp.2011.43","volume":"36","author":"VS Dalton","year":"2011","unstructured":"Dalton VS, Long LE, Weickert CS et al (2011) Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 36:1620\u20131630","journal-title":"Neuropsychopharmacology"},{"key":"9_CR31","first-page":"2","volume":"19","author":"N De Marchi","year":"2003","unstructured":"De Marchi N, De Petrocellis L, Orlando P et al (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 19:2\u20135","journal-title":"Lipids Health Dis"},{"key":"9_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","volume":"103","author":"B Dean","year":"2001","unstructured":"Dean B, Sundram S, Bradbury R et al (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9\u201315","journal-title":"Neuroscience"},{"key":"9_CR33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1460-9568.2004.03556.x","volume":"20","author":"A Degroot","year":"2004","unstructured":"Degroot A, Nomikos GG (2004) Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 20:1059\u20131064","journal-title":"Eur J Neurosci"},{"key":"9_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1192\/bjp.bp.109.064220","volume":"195","author":"M Di Forti","year":"2009","unstructured":"Di Forti M, Morgan C, Dazzan P et al (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488\u2013491","journal-title":"Br J Psychiatry"},{"key":"9_CR35","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/npp.2012.100","volume":"37","author":"A Dlugos","year":"2012","unstructured":"Dlugos A, Childs E, Stuhr KL et al (2012) Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 37:2416\u20132427","journal-title":"Neuropsychopharmacology"},{"key":"9_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.euroneuro.2008.05.003","volume":"18","author":"K Domschke","year":"2008","unstructured":"Domschke K, Dannlowski U, Ohrmann P et al (2008) Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18:751\u2013759","journal-title":"Eur Neuropsychopharmacol"},{"key":"9_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.neuropharm.2011.06.019","volume":"62","author":"LM Dono","year":"2012","unstructured":"Dono LM, Currie PJ (2012) The cannabinoid receptor CB1 inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala. Neuropharmacology 62:192\u2013199","journal-title":"Neuropharmacology"},{"key":"9_CR38","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/npp.2012.36","volume":"37","author":"S Dubreucq","year":"2012","unstructured":"Dubreucq S, Matias I, Cardinal P et al (2012) Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37:1885\u20131900","journal-title":"Neuropsychopharmacology"},{"key":"9_CR39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","volume":"65","author":"SM Eggan","year":"2008","unstructured":"Eggan SM, Hashimoto T, Lewis DA (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65:772\u2013784","journal-title":"Arch Gen Psychiatry"},{"key":"9_CR40","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/npp.2010.75","volume":"35","author":"SM Eggan","year":"2010","unstructured":"Eggan SM, Stoyak SR, Verrico CD et al (2010) Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 35:2060\u20132071","journal-title":"Neuropsychopharmacology"},{"key":"9_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19\u201327","journal-title":"J Psychopharmacol"},{"key":"9_CR42","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.schres.2014.04.028","volume":"156","author":"R Ferretjans","year":"2014","unstructured":"Ferretjans R, de Campos SM, Ribeiro-Santos R et al (2014) Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophr Res 156:254\u2013260","journal-title":"Schizophr Res"},{"key":"9_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1755-5949.2008.00071.x","volume":"15","author":"GA Fraser","year":"2009","unstructured":"Fraser GA (2009) The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 15:84\u201388","journal-title":"CNS Neurosci Ther"},{"key":"9_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00213-013-3042-8","volume":"228","author":"JC Gamble-George","year":"2013","unstructured":"Gamble-George JC, Conger JR, Hartley ND et al (2013) Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl) 228:401\u2013409","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1476-5381.2011.01625.x","volume":"165","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2012","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, Garc\u00eda-Bueno B, Zoppi S et al (2012) Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol 165:951\u2013964","journal-title":"Br J Pharmacol"},{"key":"9_CR46","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","volume":"29","author":"A Giuffrida","year":"2004","unstructured":"Giuffrida A, Leweke FM, Gerth CW et al (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108\u20132114","journal-title":"Neuropsychopharmacology"},{"key":"9_CR47","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.pnpbp.2010.11.027","volume":"35","author":"FV Gomes","year":"2011","unstructured":"Gomes FV, Casarotto PC, Resstel LB et al (2011) Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry 35:434\u2013438","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9_CR48","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.pnpbp.2010.11.021","volume":"35","author":"BB Gorzalka","year":"2011","unstructured":"Gorzalka BB, Hill MN (2011) Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 35:1575\u20131585","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.biopsych.2004.10.032","volume":"57","author":"G Griebel","year":"2005","unstructured":"Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261\u2013267","journal-title":"Biol Psychiatry"},{"key":"9_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1017\/S1461145710000209","volume":"14","author":"C Guidali","year":"2011","unstructured":"Guidali C, Vigan\u00f2 D, Petrosino S et al (2011) Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int J Neuropsychopharmacol 14:17\u201328","journal-title":"Int J Neuropsychopharmacol"},{"key":"9_CR51","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.tips.2013.08.008","volume":"34","author":"O Gunduz-Cinar","year":"2013","unstructured":"Gunduz-Cinar O, Hill MN, McEwen BS et al (2013a) FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34:637\u2013644","journal-title":"Trends Pharmacol Sci"},{"key":"9_CR52","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/mp.2012.72","volume":"18","author":"O Gunduz-Cinar","year":"2013","unstructured":"Gunduz-Cinar O, MacPherson KP, Cinar R et al (2013b) Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18:813\u2013823","journal-title":"Mol Psychiatry"},{"key":"9_CR53","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1046\/j.1460-9568.2002.02192.x","volume":"16","author":"J Haller","year":"2002","unstructured":"Haller J, Bakos N, Szirmay M et al (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395\u20131398","journal-title":"Eur J Neurosci"},{"key":"9_CR54","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/j.1460-9568.2004.03293.x","volume":"19","author":"J Haller","year":"2004","unstructured":"Haller J, Varga B, Ledent C et al (2004) Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behavior in mice. Eur J Neurosci 19:1906\u20131912","journal-title":"Eur J Neurosci"},{"key":"9_CR55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00008877-200509000-00014","volume":"16","author":"J Haller","year":"2005","unstructured":"Haller J, Szirmai M, Varga B et al (2005) Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 16:415\u2013422","journal-title":"Behav Pharmacol"},{"key":"9_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00213-009-1494-7","volume":"204","author":"J Haller","year":"2009","unstructured":"Haller J, Barna I, Barsvari B et al (2009) Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204:607\u2013616","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062741","volume":"8","author":"D Hauer","year":"2013","unstructured":"Hauer D, Schelling G, Gola H et al (2013) Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One 8, e62741","journal-title":"PLoS One"},{"key":"9_CR58","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00008877-200509000-00006","volume":"16","author":"MN Hill","year":"2005","unstructured":"Hill MN, Gorzalka BB (2005) Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 16:333\u2013352","journal-title":"Behav Pharmacol"},{"key":"9_CR59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neuroscience.2011.12.030","volume":"204","author":"MN Hill","year":"2012","unstructured":"Hill MN, Tasker JG (2012) Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204:5\u201316","journal-title":"Neuroscience"},{"key":"9_CR60","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/sj.npp.1300601","volume":"30","author":"MN Hill","year":"2005","unstructured":"Hill MN, Patel S, Carrier EJ et al (2005) Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30:508\u2013515","journal-title":"Neuropsychopharmacology"},{"key":"9_CR61","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/j.1471-4159.2008.05567.x","volume":"106","author":"MN Hill","year":"2008","unstructured":"Hill MN, Carrier EJ, McLaughlin RJ et al (2008) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106:2322\u20132336","journal-title":"J Neurochem"},{"key":"9_CR62","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","volume":"34","author":"MN Hill","year":"2009","unstructured":"Hill MN, Miller GE, Carrier EJ et al (2009) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34:1257\u20131262","journal-title":"Psychoneuroendocrinology"},{"key":"9_CR63","doi-asserted-by":"publisher","first-page":"10506","DOI":"10.1523\/JNEUROSCI.0496-11.2011","volume":"31","author":"MN Hill","year":"2011","unstructured":"Hill MN, McLaughlin RJ, Pan B et al (2011) Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 31:10506\u201310515","journal-title":"J Neurosci"},{"key":"9_CR64","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.psyneuen.2013.08.004","volume":"38","author":"MN Hill","year":"2013","unstructured":"Hill MN, Bierer LM, Makotkine I et al (2013a) Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 38:2952\u20132961","journal-title":"Psychoneuroendocrinology"},{"key":"9_CR65","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/mp.2012.90","volume":"18","author":"MN Hill","year":"2013","unstructured":"Hill MN, Kumar SA, Filipski SB et al (2013b) Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 18:1125\u20131135","journal-title":"Mol Psychiatry"},{"key":"9_CR66","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1017\/S1461145710000453","volume":"13","author":"J Horder","year":"2010","unstructured":"Horder J, Harmer CJ, Cowen PJ et al (2010) Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol 13:1103\u20131113","journal-title":"Int J Neuropsychopharmacol"},{"key":"9_CR67","first-page":"1689","volume":"47","author":"AG Horti","year":"2006","unstructured":"Horti AG, Fan H, Kuwabara H et al (2006) 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 47:1689\u20131696","journal-title":"J Nucl Med"},{"key":"9_CR68","doi-asserted-by":"crossref","first-page":"10311","DOI":"10.1523\/JNEUROSCI.23-32-10311.2003","volume":"23","author":"YC Huang","year":"2003","unstructured":"Huang YC, Wang SJ, Chiou LC et al (2003) Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 23:10311\u201310320","journal-title":"J Neurosci"},{"key":"9_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/sj.mp.4001376","volume":"9","author":"BL Hungund","year":"2004","unstructured":"Hungund BL, Vinod KY, Kassir SA et al (2004) Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9:184\u2013190","journal-title":"Mol Psychiatry"},{"key":"9_CR70","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","volume":"67","author":"H Ishiguro","year":"2010","unstructured":"Ishiguro H, Horiuchi Y, Ishikawa M et al (2010) Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67:974\u2013982","journal-title":"Biol Psychiatry"},{"key":"9_CR71","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1601-183X.2009.00512.x","volume":"8","author":"W Jacob","year":"2009","unstructured":"Jacob W, Yassouridis A, Marsicano G et al (2009) Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 8:685\u2013698","journal-title":"Genes Brain Behav"},{"key":"9_CR72","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.bbr.2012.05.025","volume":"233","author":"CS John","year":"2012","unstructured":"John CS, Currie PJ (2012) N-arachidonoyl-serotonin in the basolateral amygdala increases anxiolytic behavior in the elevated plus maze. Behav Brain Res 233:382\u2013388","journal-title":"Behav Brain Res"},{"key":"9_CR73","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/npp.2009.19","volume":"34","author":"G Juhasz","year":"2009","unstructured":"Juhasz G, Chase D, Pegg E et al (2009) CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 34:2019\u20132027","journal-title":"Neuropsychopharmacology"},{"key":"9_CR74","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.1523\/JNEUROSCI.0153-06.2006","volume":"26","author":"K Kamprath","year":"2006","unstructured":"Kamprath K, Marsicano G, Tang J et al (2006) Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 26:6677\u20136686","journal-title":"J Neurosci"},{"key":"9_CR75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1601-183X.2008.00463.x","volume":"8","author":"K Kamprath","year":"2009","unstructured":"Kamprath K, Plendl W, Marsicano G et al (2009) Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav 8:203\u2013211","journal-title":"Genes Brain Behav"},{"key":"9_CR76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pnpbp.2003.10.007","volume":"28","author":"JW Kasckow","year":"2004","unstructured":"Kasckow JW, Mulchahey JJ, Geracioti TD Jr (2004) Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 28:291\u2013295","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9_CR77","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nm803","volume":"9","author":"S Kathuria","year":"2003","unstructured":"Kathuria S, Gaetani S, Fegley D et al (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76\u201381","journal-title":"Nat Med"},{"key":"9_CR78","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","volume":"31","author":"DL Kelly","year":"2011","unstructured":"Kelly DL, Gorelick DA, Conley RR et al (2011) Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 31:86\u201391","journal-title":"J Clin Psychopharmacol"},{"key":"9_CR79","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","volume":"249","author":"DM Kerr","year":"2013","unstructured":"Kerr DM, Downey L, Conboy M et al (2013) Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res 249:124\u2013132","journal-title":"Behav Brain Res"},{"key":"9_CR80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pbb.2010.12.002","volume":"98","author":"SG Kinsey","year":"2011","unstructured":"Kinsey SG, O'Neal ST, Long JZ et al (2011) Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98:21\u201327","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR81","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuropharm.2012.03.024","volume":"66","author":"T Kiritoshi","year":"2013","unstructured":"Kiritoshi T, Sun H, Ren W et al (2013) Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. Neuropharmacology 66:170\u2013178","journal-title":"Neuropharmacology"},{"key":"9_CR82","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","volume":"114","author":"D Koethe","year":"2007","unstructured":"Koethe D, Llenos IC, Dulay JR et al (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114:1055\u20131063","journal-title":"J Neural Transm"},{"key":"9_CR83","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","volume":"194","author":"D Koethe","year":"2009","unstructured":"Koethe D, Giuffrida A, Schreiber D et al (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194:371\u2013372","journal-title":"Br J Psychiatry"},{"key":"9_CR84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fphar.2014.00010","volume":"5","author":"R Levin","year":"2014","unstructured":"Levin R, Peres FF, Almeida V et al (2014) Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. Front Pharmacol 5:10","journal-title":"Front Pharmacol"},{"key":"9_CR85","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","volume":"10","author":"FM Leweke","year":"1999","unstructured":"Leweke FM, Giuffrida A, Wurster U et al (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665\u20131669","journal-title":"Neuroreport"},{"key":"9_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2, e94","journal-title":"Transl Psychiatry"},{"key":"9_CR87","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.brainresbull.2011.07.011","volume":"86","author":"QS Lin","year":"2011","unstructured":"Lin QS, Yang Q, Liu DD et al (2011) Hippocampal endocannabinoids play an important role in induction of long-term potentiation and regulation of contextual fear memory formation. Brain Res Bull 86:139\u2013145","journal-title":"Brain Res Bull"},{"key":"9_CR88","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2008.07.032","volume":"593","author":"SF Lisboa","year":"2008","unstructured":"Lisboa SF, Resstel LB, Aguiar DC et al (2008) Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 593:73\u201378","journal-title":"Eur J Pharmacol"},{"key":"9_CR89","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/gbb.12045","volume":"12","author":"Y Litvin","year":"2013","unstructured":"Litvin Y, Phan A, Hill MN et al (2013) CB1 receptor signaling regulates social anxiety and memory. Genes Brain Behav 12:479\u2013489","journal-title":"Genes Brain Behav"},{"key":"9_CR90","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1046\/j.1460-9568.2002.01957.x","volume":"15","author":"M Maccarrone","year":"2002","unstructured":"Maccarrone M, Valverde O, Barbaccia ML et al (2002) Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci 15:1178\u20131186","journal-title":"Eur J Neurosci"},{"key":"9_CR91","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1523\/JNEUROSCI.3303-06.2007","volume":"27","author":"R Marsch","year":"2007","unstructured":"Marsch R, Foeller E, Rammes G et al (2007) Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 27:832\u2013839","journal-title":"J Neurosci"},{"key":"9_CR92","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature00839","volume":"418","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Wotjak CT, Azad SC et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530\u2013534","journal-title":"Nature"},{"key":"9_CR93","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","volume":"159","author":"M Martin","year":"2002","unstructured":"Martin M, Ledent C, Parmentier M et al (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379\u2013387","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR94","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.bbr.2012.09.053","volume":"237","author":"RJ McLaughlin","year":"2013","unstructured":"McLaughlin RJ, Hill MN, Dang SS et al (2013) Upregulation of CB1 receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res 237:333\u2013337","journal-title":"Behav Brain Res"},{"key":"9_CR95","doi-asserted-by":"publisher","first-page":"10707","DOI":"10.1523\/JNEUROSCI.3502-04.2004","volume":"24","author":"M Melis","year":"2004","unstructured":"Melis M, Perra S, Muntoni AL et al (2004) Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707\u201310715","journal-title":"J Neurosci"},{"key":"9_CR96","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","volume":"161","author":"HY Meltzer","year":"2004","unstructured":"Meltzer HY, Arvanitis L, Bauer D et al (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975\u2013984","journal-title":"Am J Psychiatry"},{"key":"9_CR97","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/mp.2012.145","volume":"18","author":"FJ Meye","year":"2013","unstructured":"Meye FJ, Trezza V, Vanderschuren LJ et al (2013) Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 18:1294\u20131301","journal-title":"Mol Psychiatry"},{"key":"9_CR98","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/npp.2008.98","volume":"34","author":"V Micale","year":"2009","unstructured":"Micale V, Cristino L, Tamburella A et al (2009) Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34:593\u2013606","journal-title":"Neuropsychopharmacology"},{"key":"9_CR99","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FBP.0b013e32832c70b1","volume":"20","author":"E Mikics","year":"2009","unstructured":"Mikics E, Vas J, Aliczki M et al (2009) Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 20:265\u2013272","journal-title":"Behav Pharmacol"},{"key":"9_CR100","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jad.2011.05.023","volume":"134","author":"D Minocci","year":"2011","unstructured":"Minocci D, Massei J, Martino A et al (2011) Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. J Affect Disord 134:427\u2013430","journal-title":"J Affect Disord"},{"issue":"9600","key":"9_CR101","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/S0140-6736(07)61705-X","volume":"370","author":"PB Mitchell","year":"2007","unstructured":"Mitchell PB, Morris MJ (2007) Depression and anxiety with rimonabant. Lancet 370(9600):1671\u20131672","journal-title":"Lancet"},{"key":"9_CR102","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00213-013-2995-y","volume":"227","author":"M Mitjans","year":"2013","unstructured":"Mitjans M, Serretti A, Fabbri C et al (2013) Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology (Berl) 227:509\u2013519","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR103","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00213-008-1209-5","volume":"200","author":"AM Moise","year":"2008","unstructured":"Moise AM, Eisenstein SA, Astarita G et al (2008) An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl) 200:333\u2013346","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR104","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.phrs.2010.01.002","volume":"61","author":"P Monteleone","year":"2010","unstructured":"Monteleone P, Bifulco M, Maina G et al (2010) Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 61:400\u2013404","journal-title":"Pharmacol Res"},{"key":"9_CR105","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.neuropharm.2006.10.013","volume":"52","author":"FA Moreira","year":"2007","unstructured":"Moreira FA, Aguiar DC, Guimar\u00e3es FS (2007) Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52:958\u2013965","journal-title":"Neuropharmacology"},{"key":"9_CR106","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neuropharm.2007.07.005","volume":"54","author":"FA Moreira","year":"2008","unstructured":"Moreira FA, Kaiser N, Monory K et al (2008) Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54:141\u2013150","journal-title":"Neuropharmacology"},{"key":"9_CR107","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.schres.2013.06.013","volume":"148","author":"C Muguruza","year":"2013","unstructured":"Muguruza C, Lehtonen M, Aaltonen N et al (2013) Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res 148:145\u2013150","journal-title":"Schizophr Res"},{"key":"9_CR108","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pbb.2007.11.001","volume":"89","author":"N Naderi","year":"2008","unstructured":"Naderi N, Haghparast A, Saber-Tehrani A et al (2008) Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 89:64\u201375","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR109","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00213-006-0689-4","volume":"192","author":"PS Naidu","year":"2007","unstructured":"Naidu PS, Varvel SA, Ahn K et al (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192:61\u201370","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR110","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/00001756-199701200-00023","volume":"8","author":"M Navarro","year":"1997","unstructured":"Navarro M, Hernandez E, Munoz RM et al (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491\u2013496","journal-title":"Neuroreport"},{"key":"9_CR111","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mp.2013.61","volume":"18","author":"A Neumeister","year":"2013","unstructured":"Neumeister A, Normandin MD, Pietrzak RH et al (2013) Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18:1034\u20131040","journal-title":"Mol Psychiatry"},{"key":"9_CR112","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","volume":"172","author":"KA Newell","year":"2006","unstructured":"Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172:556\u2013560","journal-title":"Exp Brain Res"},{"key":"9_CR113","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.pbb.2012.10.008","volume":"103","author":"LD O\u2019Brien","year":"2013","unstructured":"O\u2019Brien LD, Wills KL, Segsworth B et al (2013) Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 103:597\u2013602","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001640","volume":"3","author":"ES Onaivi","year":"2008","unstructured":"Onaivi ES, Ishiguro H, Gong JP et al (2008) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 3, e1640","journal-title":"PLoS One"},{"key":"9_CR115","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/npp.2011.34","volume":"36","author":"A Ortega-Alvaro","year":"2011","unstructured":"Ortega-Alvaro A, Aracil-Fern\u00e1ndez A, Garc\u00eda-Guti\u00e9rrez MS et al (2011) Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 36:1489\u20131504","journal-title":"Neuropsychopharmacology"},{"key":"9_CR116","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/acprof:oso\/9780199662685.003.0028","volume-title":"Handbook of Cannabis","author":"D Parolaro","year":"2014","unstructured":"Parolaro D, Zamberletti E, Rubino T (2014) Cannabidiol\/Phytocannabinoids: a new opportunity for schizophrenia treatment. In: Pertwee R (ed) Handbook of Cannabis. Oxford University Press edn, Oxford, pp 526\u2013537"},{"key":"9_CR117","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1124\/jpet.106.101287","volume":"318","author":"S Patel","year":"2006","unstructured":"Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304\u2013311","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR118","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1530-0277.2007.00588.x","volume":"32","author":"S Perra","year":"2008","unstructured":"Perra S, Pillolla G, Luchicchi A et al (2008) Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system. Alcohol Clin Exp Res 32:443\u2013449","journal-title":"Alcohol Clin Exp Res"},{"key":"9_CR119","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.1523\/JNEUROSCI.6038-09.2010","volume":"30","author":"W Plendl","year":"2010","unstructured":"Plendl W, Wotjak CT (2010) Dissociation of within- and between-session extinction of conditioned fear. J Neurosci 30:4990\u20134998","journal-title":"J Neurosci"},{"key":"9_CR120","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.schres.2007.04.022","volume":"100","author":"S Potvin","year":"2008","unstructured":"Potvin S, Joyal CC, Pelletier J et al (2008) Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res 100:242\u2013251","journal-title":"Schizophr Res"},{"key":"9_CR121","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neuropharm.2010.09.003","volume":"60","author":"N Realini","year":"2011","unstructured":"Realini N, Vigano\u2019 D, Guidali C et al (2011) Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology 60:235\u2013243","journal-title":"Neuropharmacology"},{"key":"9_CR122","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbr.2009.05.013","volume":"203","author":"CG Reich","year":"2009","unstructured":"Reich CG, Taylor ME, McCarthy MM (2009) Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behav Brain Res 203:264\u2013269","journal-title":"Behav Brain Res"},{"key":"9_CR123","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/npp.2012.123","volume":"37","author":"AA Rey","year":"2012","unstructured":"Rey AA, Purrio M, Viveros MP et al (2012) Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37:2624\u20132634","journal-title":"Neuropsychopharmacology"},{"key":"9_CR124","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.brainres.2010.04.031","volume":"1343","author":"SA Robinson","year":"2010","unstructured":"Robinson SA, Loiacono RE, Christopoulos A et al (2010) The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. Brain Res 1343:153\u2013167","journal-title":"Brain Res"},{"key":"9_CR125","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1046\/j.1460-9568.2003.02548.x","volume":"17","author":"RJ Rodgers","year":"2003","unstructured":"Rodgers RJ, Haller J, Halasz J et al (2003) \u2018One-trial sensitization\u2019 to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 17:1279\u20131286","journal-title":"Eur J Neurosci"},{"key":"9_CR126","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/00008877-200509000-00013","volume":"16","author":"RJ Rodgers","year":"2005","unstructured":"Rodgers RJ, Evans PM, Murphy A (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16:405\u2013413","journal-title":"Behav Pharmacol"},{"key":"9_CR127","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1742-7843.2009.00449.x","volume":"105","author":"A Roohbakhsh","year":"2009","unstructured":"Roohbakhsh A, Keshavarz S, Hasanein P et al (2009) Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours. Basic Clin Pharmacol Toxicol 105:333\u2013338","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"9_CR128","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/cercor\/bhm161","volume":"18","author":"T Rubino","year":"2008","unstructured":"Rubino T, Realini N, Castiglioni C et al (2008a) Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18:1292\u20131301","journal-title":"Cereb Cortex"},{"key":"9_CR168","doi-asserted-by":"crossref","unstructured":"Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P, Parolaro D. (2008b). CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 54, 151-160.","DOI":"10.1016\/j.neuropharm.2007.06.024"},{"key":"9_CR129","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12640-009-9031-3","volume":"15","author":"T Rubino","year":"2009","unstructured":"Rubino T, Realini N, Braida D et al (2009) The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 15:291\u2013302","journal-title":"Neurotox Res"},{"key":"9_CR130","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.neuropharm.2008.02.005","volume":"54","author":"M Rubio","year":"2008","unstructured":"Rubio M, Fernandez-Ruiz J, De Miguel R et al (2008) CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. Neuropharmacology 54:976\u2013988","journal-title":"Neuropharmacology"},{"key":"9_CR131","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/0269881111408958","volume":"26","author":"S Ruehle","year":"2012","unstructured":"Ruehle S, Rey AA, Remmers F et al (2012) The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 26:23\u201339","journal-title":"J Psychopharmacol"},{"key":"9_CR132","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00213-004-1877-8","volume":"176","author":"C Sanchis-Segura","year":"2004","unstructured":"Sanchis-Segura C, Cline BH, Marsicano G et al (2004) Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 176:223\u2013232","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR133","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/FBP.0b013e3283095234","volume":"19","author":"CJ Santos","year":"2008","unstructured":"Santos CJ, Stern CA, Bertoglio LJ (2008) Attenuation of anxiety-related behavior after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. Behav Pharmacol 19:357\u2013360","journal-title":"Behav Pharmacol"},{"key":"9_CR134","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neuropharm.2007.08.011","volume":"54","author":"M Scherma","year":"2008","unstructured":"Scherma M, Medalie J, Fratta W et al (2008) The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54:129\u2013140","journal-title":"Neuropharmacology"},{"key":"9_CR135","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","volume":"130","author":"CD Schubart","year":"2011","unstructured":"Schubart CD, Sommer IE, van Gastel WA et al (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216\u2013221","journal-title":"Schizophr Res"},{"key":"9_CR136","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.phrs.2011.04.010","volume":"64","author":"NR Sciolino","year":"2011","unstructured":"Sciolino NR, Zhou W, Hohmann AG (2011) Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64:226\u2013234","journal-title":"Pharmacol Res"},{"key":"9_CR137","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neulet.2007.08.008","volume":"426","author":"J Seifert","year":"2007","unstructured":"Seifert J, Ossege S, Emrich HM et al (2007) No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett 426:29\u201333","journal-title":"Neurosci Lett"},{"key":"9_CR138","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1017\/S146114570999023X","volume":"13","author":"A Seillier","year":"2010","unstructured":"Seillier A, Advani T, Cassano T et al (2010) Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol 13:373\u2013386","journal-title":"Int J Neuropsychopharmacol"},{"key":"9_CR139","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/npp.2013.81","volume":"38","author":"A Seillier","year":"2013","unstructured":"Seillier A, Martinez AA, Giuffrida A (2013) Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia. Neuropsychopharmacology 38:1816\u20131824","journal-title":"Neuropsychopharmacology"},{"key":"9_CR140","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/npp.2009.83","volume":"35","author":"LM Shin","year":"2010","unstructured":"Shin LM, Liberzon I (2010) The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 35:169\u2013191","journal-title":"Neuropsychopharmacology"},{"key":"9_CR141","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/sj.npp.1301476","volume":"33","author":"KS Sink","year":"2008","unstructured":"Sink KS, McLaughlin PJ, Wood JA et al (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946\u2013955","journal-title":"Neuropsychopharmacology"},{"key":"9_CR142","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.pbb.2010.03.011","volume":"95","author":"KS Sink","year":"2010","unstructured":"Sink KS, Segovia KN, Collins LE et al (2010a) The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav 95:479\u2013484","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR143","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.euroneuro.2009.11.002","volume":"20","author":"KS Sink","year":"2010","unstructured":"Sink KS, Segovia KN, Sink J et al (2010b) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists\/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20:112\u2013122","journal-title":"Eur Neuropsychopharmacol"},{"key":"9_CR144","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.euroneuro.2009.09.004","volume":"20","author":"MS Spano","year":"2010","unstructured":"Spano MS, Fadda P, Frau R et al (2010) Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol 20:25\u201336","journal-title":"Eur Neuropsychopharmacol"},{"key":"9_CR145","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.tpj.6500466","volume":"8","author":"MA Steiner","year":"2008","unstructured":"Steiner MA, Wanisch K, Monory K et al (2008) Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 8:196\u2013208","journal-title":"Pharmacogenomics J"},{"key":"9_CR146","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.euroneuro.2008.11.004","volume":"19","author":"AL Terzian","year":"2009","unstructured":"Terzian AL, Aguiar DC, Guimar\u00e3es FS et al (2009) Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 19:188\u2013195","journal-title":"Eur Neuropsychopharmacol"},{"key":"9_CR147","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bbr.2008.12.035","volume":"200","author":"G Thiemann","year":"2009","unstructured":"Thiemann G, Watt CA, Ledent C et al (2009) Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav Brain Res 200:60\u201367","journal-title":"Behav Brain Res"},{"key":"9_CR148","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fnbeh.2013.00100","volume":"7","author":"V Trezza","year":"2013","unstructured":"Trezza V, Campolongo P (2013) The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Front Behav Neurosci 7:100","journal-title":"Front Behav Neurosci"},{"key":"9_CR149","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00041444-200010030-00008","volume":"10","author":"SJ Tsai","year":"2000","unstructured":"Tsai SJ, Wang YC, Hong CJ (2000) Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet 10:149\u2013151","journal-title":"Psychiatr Genet"},{"key":"9_CR150","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.mp.4001029","volume":"7","author":"H Ujike","year":"2002","unstructured":"Ujike H, Takaki M, Nakata K et al (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515\u2013518","journal-title":"Mol Psychiatry"},{"key":"9_CR151","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.neuropharm.2004.01.003","volume":"46","author":"L Uriguen","year":"2004","unstructured":"Uriguen L, Perez-Rial S, Ledent C et al (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46:966\u2013973","journal-title":"Neuropharmacology"},{"key":"9_CR152","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","volume":"206","author":"L Uriguen","year":"2009","unstructured":"Uriguen L, Garc\u00eda-Fuster MJ, Callado LF et al (2009) Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 206:313\u2013324","journal-title":"Psychopharmacology (Berl)"},{"key":"9_CR153","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pbb.2012.09.016","volume":"103","author":"B Varga","year":"2012","unstructured":"Varga B, Kassai F, Gyertyan I (2012) Interactions of CB1 and mGLU5 receptor antagonists in food intake, anxiety and memory models in rats. Pharmacol Biochem Behav 103:425\u2013430","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR154","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1124\/jpet.301.3.915","volume":"301","author":"SA Varvel","year":"2002","unstructured":"Varvel SA, Lichtman AH (2002) Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301:915\u2013924","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR155","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2458-8-92","volume":"8","author":"S Vetter","year":"2008","unstructured":"Vetter S, Rossegger A, Rossler W et al (2008) Exposure to the tsunami disaster, PTSD symptoms and increased substance use - an Internet based survey of male and female residents of Switzerland. BMC Public Health 8:92","journal-title":"BMC Public Health"},{"key":"9_CR156","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1017\/S1461145708009371","volume":"12","author":"D Vigan\u00f2","year":"2009","unstructured":"Vigan\u00f2 D, Guidali C, Petrosino S et al (2009) Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol 12:599\u2013614","journal-title":"Int J Neuropsychopharmacol"},{"key":"9_CR157","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jpsychires.2009.11.013","volume":"44","author":"KY Vinod","year":"2010","unstructured":"Vinod KY, Kassir SA, Hungund BL et al (2010) Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatr Res 44:591\u2013597","journal-title":"J Psychiatr Res"},{"key":"9_CR158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036743","volume":"7","author":"KY Vinod","year":"2012","unstructured":"Vinod KY, Xie S, Psychoyos D et al (2012) Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats. PLoS One 7, e36743","journal-title":"PLoS One"},{"key":"9_CR159","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","volume":"81","author":"M Viveros","year":"2005","unstructured":"Viveros M, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331\u2013342","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR160","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","volume":"159","author":"DW Volk","year":"2014","unstructured":"Volk DW, Eggan SM, Horti AG et al (2014) Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophr Res 159:124\u2013129","journal-title":"Schizophr Res"},{"key":"9_CR161","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","volume":"52","author":"DF Wong","year":"2010","unstructured":"Wong DF, Kuwabara H, Horti AG et al (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 52:1505\u20131513","journal-title":"Neuroimage"},{"key":"9_CR162","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1017\/S1461145710001185","volume":"15","author":"E Zamberletti","year":"2010","unstructured":"Zamberletti E, Vigan\u00f2 D, Guidali C et al (2010) Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol 15:267\u2013280","journal-title":"Int J Neuropsychopharmacol"},{"key":"9_CR163","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/j.1476-5381.2012.02095.x","volume":"167","author":"E Zamberletti","year":"2012","unstructured":"Zamberletti E, Piscitelli F, Cadeddu F et al (2012a) Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. Br J Pharmacol 167:1652\u20131664","journal-title":"Br J Pharmacol"},{"key":"9_CR164","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.2174\/138161212802884744","volume":"18","author":"E Zamberletti","year":"2012","unstructured":"Zamberletti E, Rubino T, Parolaro D (2012b) The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharm Des 18:4980\u20134990","journal-title":"Curr Pharm Des"},{"key":"9_CR165","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1192\/bjp.bp.107.036129","volume":"191","author":"S Zammit","year":"2007","unstructured":"Zammit S, Spurlock G, Williams H et al (2007) Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 191:402\u2013407","journal-title":"Br J Psychiatry"},{"key":"9_CR166","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","volume":"28","author":"K Zavitsanou","year":"2004","unstructured":"Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355\u2013360","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9_CR167","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/npp.2014.24","volume":"39","author":"P Zhong","year":"2014","unstructured":"Zhong P, Wang W, Pan B et al (2014) Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 39:1763\u20131776","journal-title":"Neuropsychopharmacology"}],"container-title":["Handbook of Experimental Pharmacology","Endocannabinoids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-20825-1_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T13:12:54Z","timestamp":1676034774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-20825-1_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319208244","9783319208251"],"references-count":168,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-20825-1_9","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}